Comparison of the AmpFire® Multiplex HPV Assay to the Xpert® HPV Assay for detection of human papillomavirus and cervical disease in women with human immunodeficiency virus: a pragmatic performance evaluation

Infect Agents Cancer

The research study titled “Comparison of AmpFire® Multiplex HPV Assay to Xpert® HPV Assay for detecting human papillomavirus (HPV) and cervical disease in women with human immunodeficiency virus (HIV)” aimed to evaluate the performance of two different HPV testing methods in women living with HIV.

HPV is a common sexually transmitted infection that can lead to cervical cancer in some cases. Women with HIV are particularly vulnerable to developing HPV-related cervical diseases, making regular HPV screening crucial for their health and well-being.

This study compared two HPV testing methods: the AmpFire® Multiplex HPV Assay and the Xpert® HPV Assay. Both assays are used to detect the presence of HPV in cervical samples, helping identify women at risk of developing cervical disease.

A large group of women living with HIV participated in the study. The researchers analyzed samples from these women using both the AmpFire® and Xpert® assays, and the results were compared to determine the accuracy and reliability of each test.

The study’s findings will provide valuable insights into the performance of these HPV testing methods in the context of women with HIV. Understanding which assay performs better in this specific population will be essential in improving HPV screening strategies and enhancing early detection of cervical disease.

By evaluating the effectiveness of these two HPV testing methods, the research aims to support healthcare professionals in making informed decisions about the most appropriate screening tools for women with HIV. Ultimately, this could lead to better management of HPV-related cervical diseases and improved health outcomes for this vulnerable population. In conclusion, this study seeks to assess the practical performance of the AmpFire® Multiplex HPV Assay and the Xpert® HPV Assay in detecting HPV and cervical disease in women living with HIV. The results will contribute to the development of more effective and tailored screening approaches, promoting early detection and timely intervention to protect the health and well-being of women at higher risk of HPV-related cervical issues.

Disclaimer: This lay summary was generated by AI and has not been approved by any of the authors yet.

SANTHE is an Africa Health Research Institute (AHRI) flagship programme funded by the Science for Africa Foundation through the DELTAS Africa programme; the Bill & Melinda Gates Foundation; Gilead Sciences Inc.; and the Ragon Institute of Mass General, MIT, and Harvard.